⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRVO News
CervoMed Inc. Common Stock
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
globenewswire.com
CRVO
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
globenewswire.com
CRVO